Cel Sci CORP (CVM) — SEC Filings

Overview

Cel Sci CORP (CVM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1 filed on Apr 17, 2026: CEL-SCI Corporation filed an S-1 form on April 17, 2026, to register securities. The filing includes exhibits such as a placement agent agreement, legal opinions, and consents from BDO USA PC and HART HART LLC. The company, operating in the biological products sector, is located at 8229 Boone Blvd.,

Sentiment Summary

Across 29 filings, the sentiment breakdown is: 5 bearish, 23 neutral, 1 mixed. The dominant filing sentiment for Cel Sci CORP is neutral.

Filing Type Overview

Cel Sci CORP (CVM) has filed 1 S-1, 2 10-K, 18 8-K, 6 10-Q, 1 DEF 14A, 1 DEFA14A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (29)

• CEL-SCI Files S-1 for Security Registration — S-1 · Apr 17, 2026 Risk: medium
  CEL-SCI Corporation filed an S-1 form on April 17, 2026, to register securities. The filing includes exhibits such as a placement agent agreement, legal opinion
• CEL-SCI Pushes Multikine to Confirmatory Study After Strong Phase III Data — 10-K · Dec 29, 2025 Risk: high
  CEL-SCI Corporation, a late clinical-stage biotechnology company, reported no revenue for the fiscal year ended September 30, 2025, as its lead product candidat
• CEL-SCI Corp Files 8-K on Security Holder Rights — 8-K · Nov 24, 2025 Risk: medium
  CEL-SCI Corporation filed an 8-K on November 24, 2025, reporting events as of November 18, 2025. The filing indicates material modifications to the rights of se
• CEL-SCI Corp Files 8-K on Security Holder Rights — 8-K · Nov 5, 2025 Risk: low
  CEL-SCI Corporation filed an 8-K on November 5, 2025, reporting material modifications to the rights of security holders and financial statements as of October
• CEL-SCI CORP Files 8-K: Material Definitive Agreement — 8-K · Aug 29, 2025 Risk: medium
  On August 27, 2025, CEL-SCI CORPORATION (CELC) entered into a material definitive agreement. The company, incorporated in Colorado with its principal executive
• CEL-SCI CORP Files 8-K Under 'Other Events' — 8-K · Aug 25, 2025 Risk: medium
  CEL-SCI CORPORATION filed an 8-K on August 25, 2025, reporting an event that occurred on August 22, 2025. The filing is categorized under 'Other Events' and doe
• CEL-SCI Narrows Q3 Loss Amid Cash Burn, Post-Split Share Count — 10-Q · Aug 14, 2025 Risk: high
  CEL-SCI Corporation reported a net loss of $19,310,155 for the nine months ended June 30, 2025, a decrease from the $20,810,973 net loss in the prior year perio
• CEL-SCI CORP Enters Material Definitive Agreement — 8-K · Jul 14, 2025 Risk: medium
  On July 11, 2025, CEL-SCI CORPORATION entered into a material definitive agreement. The company also reported other events and filed financial statements and ex
• CEL-SCI CORP Enters Material Definitive Agreement — 8-K · May 23, 2025 Risk: medium
  CEL-SCI CORPORATION (CIC) announced on May 21, 2025, that it entered into a material definitive agreement. The company, incorporated in Colorado with its princi
• CEL-SCI Corp Files 8-K on Security Holder Vote Matters — 8-K · May 19, 2025 Risk: low
  CEL-SCI Corporation filed an 8-K on May 19, 2025, reporting a submission of matters to a vote of security holders. The company, incorporated in Colorado, is inv
• CEL SCI CORP Q2 2025: Assets $63.8M, Liabilities $84.4M — 10-Q · May 14, 2025 Risk: high
  CEL SCI CORP filed its Q2 2025 10-Q report on May 14, 2025, for the period ending March 31, 2025. The company reported total assets of $63.79 million and total
• CEL-SCI Corp Files Preliminary Proxy Statement — DEF 14A · Apr 9, 2025 Risk: low
  CEL-SCI CORPORATION (NYSE: CVM) filed a preliminary proxy statement on April 9, 2025, for its annual meeting. The filing indicates that the company is seeking s
• CEL-SCI CORP Files 8-K: Material Definitive Agreement — 8-K · Mar 18, 2025 Risk: medium
  On March 17, 2025, CEL-SCI CORPORATION entered into a material definitive agreement. The company, incorporated in Colorado with its principal executive offices
• CEL SCI CORP Q1 2025: Minimal Revenue, High R&D Spend — 10-Q · Feb 14, 2025 Risk: high
  CEL SCI CORP filed its 10-Q for the period ending December 31, 2024. The company reported minimal revenue of $0.01 million for the first quarter of fiscal year
• CEL SCI CORP Files 2024 10-K — 10-K · Jan 13, 2025 Risk: medium
  CEL SCI CORP filed its 2024 10-K on January 13, 2025, reporting on its fiscal year ending September 30, 2024. The company, previously known as INTERLEUKIN 2 INC
• CEL-SCI CORP Files 8-K: Material Agreement & Other Events — 8-K · Dec 31, 2024 Risk: medium
  CEL-SCI CORPORATION (CIC) filed an 8-K on December 31, 2024, reporting events as of December 29, 2024. The filing indicates the entry into a material definitive
• CEL-SCI CORP: Director Changes & Officer Compensation Updates — 8-K · Nov 15, 2024 Risk: medium
  CEL-SCI CORPORATION announced on November 13, 2024, changes related to its board of directors and executive compensation. Specifically, the company reported the
• CEL-SCI Corp raises $2.45M via direct offering — 8-K · Nov 13, 2024 Risk: medium
  CEL-SCI CORPORATION announced on November 12, 2024, that it has entered into a securities purchase agreement with an institutional investor for a registered dir
• CEL-SCI CORP Files 8-K — 8-K · Sep 17, 2024 Risk: low
  CEL-SCI CORPORATION filed an 8-K on September 17, 2024, reporting an event on September 16, 2024. The filing pertains to "Other Events" and "Financial Statement
• CEL SCI CORP 10-Q: Assets $54.26M, Liabilities $47.42M — 10-Q · Aug 14, 2024 Risk: medium
  CEL SCI CORP filed its 10-Q for the period ending June 30, 2024, reporting $54.26 million in total assets and $47.42 million in total liabilities. The company's
• CEL-SCI Corp Files 8-K: Material Agreement & Other Events — 8-K · Jul 29, 2024 Risk: medium
  CEL-SCI Corporation entered into a material definitive agreement on July 26, 2024. The company also reported other events and filed financial statements and exh
• CEL-SCI Corp Files 8-K: Reporting Other Events & Exhibits — 8-K · Jul 26, 2024 Risk: low
  CEL-SCI Corporation filed an 8-K on July 26, 2024, reporting other events and financial statements/exhibits. The filing does not contain specific details on new
• CEL-SCI Receives FDA Complete Response Letter for Multikine — 8-K · Jun 20, 2024 Risk: high
  CEL-SCI Corporation announced on June 18, 2024, that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding
• CEL SCI CORP Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk: high
  CEL SCI CORP (CVM) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. CEL SCI CORP reported a net loss of $47,422,304 for the six months ended March
• CEL-SCI Corp Reports Director/Officer Changes — 8-K · Apr 23, 2024 Risk: medium
  CEL-SCI Corporation filed an 8-K on April 23, 2024, reporting changes effective April 19, 2024. The filing pertains to the departure of directors or certain off
• CEL-SCI Corp Files 8-K on Shareholder Vote Matters — 8-K · Apr 19, 2024 Risk: low
  CEL-SCI Corporation filed an 8-K on April 19, 2024, to report on matters submitted to a vote of security holders. The filing does not contain specific details a
• CEL-SCI CORP Files DEFA14A Proxy Materials — DEFA14A · Mar 7, 2024 Risk: low
  CEL-SCI CORPORATION (CVM) has filed a Definitive Additional Materials proxy statement (DEFA14A) on March 7, 2024. This filing relates to materials provided to s
• CEL SCI CORP Files 10-Q for Period Ending December 31, 2023 — 10-Q · Feb 14, 2024 Risk: high
  CEL SCI CORP (CVM) filed a Quarterly Report (10-Q) with the SEC on February 14, 2024. CEL SCI CORP reported a net loss of $47,422,304 for the quarter ended Dece
• CEL-SCI Enters Material Definitive Agreement on Feb 8 — 8-K · Feb 13, 2024 Risk: medium
  CEL-SCI Corporation (CVM) filed an 8-K on February 13, 2024, reporting an event that occurred on February 8, 2024, concerning an entry into a material definitiv

Related Companies

MRK · BMY · SCI · CELC · CIC

Frequently Asked Questions